定制剂量密集型化疗对比标准3周辅助化疗对高危早期乳腺癌女性无复发生存的影响:一项随机临床试验
该随机开放标签3期试验在瑞典、德国和奥地利86个中心纳入2017例高危早期乳腺癌女性,比较基于白细胞最低点的定制剂量密集方案与标准3周方案。定制剂量密集组无复发生存无统计学显著改善(HR 0.79,95%CI 0.61-1.01,P=0.06),无事件生存显著优于对照组(HR 0.79,95%CI 0.63-0.99,P=0.04),但3/4级非血液学毒性更常见(52.6% vs 36.6%)。
要点
- 定制剂量密集组5年无复发生存88.7%,对照组85.0%,差异未达统计学显著(P=0.06)。
- 定制剂量密集组5年无事件生存86.7% vs 对照组82.1%,HR 0.79(95%CI 0.63-0.99,P=0.04)。
- 3/4级非血液学毒性定制剂量密集组527例(52.6%)vs 对照组366例(36.6%)。
核心结论
- 在高危早期乳腺癌女性中,与标准辅助化疗相比,定制剂量密集化疗未使乳腺癌无复发生存获得统计学显著改善。
- 定制剂量密集组非血液学毒性反应更常见。
研究设计与样本
- 随机、开放标签、3期试验,于2007年2月20日至2011年9月14日在瑞典、德国和奥地利86个中心开展。
- 纳入65岁及以下、因非转移性淋巴结阳性或高危淋巴结阴性乳腺癌接受手术的女性,共随机2017例(定制剂量密集组1006例,对照组1011例),其中2000例接受至少1周期研究治疗。
- 中位年龄51岁(IQR 45-58岁),80%为激素受体阳性肿瘤,97%为淋巴结阳性疾病。
主要发现
- 中位随访5.3年(IQR 4.5-6.1年)时报告269例无复发生存事件,定制剂量密集组118例 vs 对照组151例(HR 0.79,95%CI 0.61-1.01,log-rank P=0.06;5年无复发生存率88.7% vs 85.0%)。
- 定制剂量密集组无事件生存显著优于对照组(HR 0.79,95%CI 0.63-0.99,P=0.04;5年无事件生存率86.7% vs 82.1%)。
- 两组总生存无差异(HR 0.77,95%CI 0.57-1.05,P=0.09;5年总生存率92.1% vs 90.2%)。
- 两组远处无病生存无差异(HR 0.83,95%CI 0.64-1.08,P=0.17;5年远处无病生存率89.4% vs 86.7%)。
- 3/4级非血液学毒性反应定制剂量密集组527例(52.6%) vs 对照组366例(36.6%)。
关键数值与推荐
- 定制剂量密集组方案为4周期基于白细胞最低点的定制剂量密集表柔比星和环磷酰胺每2周一次,序贯4周期定制剂量密集多西他赛每2周一次。
- 对照组方案为3周期氟尿嘧啶联合表柔比星-环磷酰胺每3周一次,序贯3周期多西他赛每3周一次。
- 主要终点为乳腺癌无复发生存;次要终点包括5年无事件生存、远处无病生存、总生存及3/4级毒性反应发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy. Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy. OBJECTIVE: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with a standard 3-weekly chemotherapy schedule. DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label, phase 3 trial of women aged 65 years and younger who had surgery for nonmetastatic node-positive or high-risk node-negative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and September 14, 2011. INTERVENTIONS: Patients were randomized 1:1 either to 4 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was breast cancer recurrence-free survival (BCRFS). Secondary end points included 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and rates of grade 3 or 4 toxic effects. RESULTS: Among 2017 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [IQR] age, 51 [45-58] years; 80% with hormone receptor-positive tumors; 97% with node-positive disease), 2000 received study treatment (≥1 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group). After a median follow-up of 5.3 years (IQR, 4.5-6.1 years), 269 BCRFS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79; 95% CI, 0.61-1.01; log-rank P = .06; 5-year BCRFS, 88.7% vs 85.0%). The tailored dose-dense group had significantly better EFS than the control group (HR, 0.79; 95% CI, 0.63-0.99; P = .04; 5-year EFS, 86.7% vs 82.1%). The groups did not differ in OS (HR, 0.77; 95% CI, 0.57-1.05; P = .09; 5-year OS, 92.1% vs 90.2%) or DDFS (HR, 0.83; 95% CI, 0.64-1.08; P = .17; 5-year DDFS, 89.4% vs 86.7%). Grade 3 or 4 nonhematologic toxic effects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group. CONCLUSIONS AND RELEVANCE: Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival. Nonhematologic toxic effects were more frequent in the tailored dose-dense group. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00798070; isrctn.org Identifier: ISRCTN39017665.
引用
- Foukakis T, von Minckwitz G, Bengtsson NO, et al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA. 2016. PMID: 27825007. doi:10.1001/jama.2016.15865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。